ALNYLAM PHARMACEUTICALS, INC. Cash and Restricted Cash
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Cash and Restricted Cash of $1.71 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.71B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.66B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.49B.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.12B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $1.71B 10-Q · filed 2026-07-30 |
| 2025-12-31 | $1.66B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.49B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.12B 10-Q · filed 2026-07-30 |
| 2025-03-31 | $1.02B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $968.65M 10-Q · filed 2026-07-30 |
| 2024-09-30 | $1.10B 10-Q · filed 2025-10-30 |
| 2024-06-30 | $971.19M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $684.72M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $814.88M 10-K · filed 2026-02-12 |
| 2023-09-30 | $1.04B 10-Q · filed 2024-10-31 |
| 2023-06-30 | $659.98M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $674.41M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $868.56M 10-K · filed 2026-02-12 |
| 2022-09-30 | $1.08B 10-Q · filed 2023-11-02 |
| 2022-06-30 | $577.74M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $536.26M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $822.15M 10-K · filed 2025-02-13 |
| 2021-09-30 | $1.10B 10-Q · filed 2022-10-27 |
| 2021-06-30 | $748.07M 10-Q · filed 2022-07-28 |
| 2020-12-31 | $499.05M 10-K · filed 2024-02-15 |
| 2018-03-31 | $397.88M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $646.83M 10-Q · filed 2018-05-04 |
| 2017-03-31 | $172.55M 10-Q · filed 2018-05-04 |
| 2016-12-31 | $195.09M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |